Rezolute to Participate in the Jefferies Global Healthcare Conference

Rhea-AI Summary

Rezolute (Nasdaq: RZLT) announced that its CEO, Nevan Charles Elam, will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 6, 2024, at 1:00 p.m. ET in New York City. The event will feature a live webcast available on Rezolute's investor relations website, which will be archived for 90 days. Additionally, the management team will engage in one-on-one meetings with investors throughout the conference.

Positive

• CEO Nevan Charles Elam's participation in a high-profile conference may increase visibility and investor interest in Rezolute.
• The live webcast offers greater access and transparency for current and potential investors.
• One-on-one investor meetings provide opportunities for personalized engagement and could lead to new investment and partnership opportunities.

Negative

• The event does not guarantee immediate financial benefits or operational improvements.
• No new clinical or financial data is being presented, which might disappoint investors seeking concrete updates.

REDWOOD CITY, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today announced that Nevan Charles Elam, Chief Executive Officer and Founder of Rezolute, will participate in a fireside chat during the Jefferies Global Healthcare Conference on Thursday, June 6, 2024, at 1:00 p.m. ET in New York City.

A live webcast will be available in the Events section of the company's investor relations website at https://ir.rezolutebio.com/news-events/ir-calendar and archived for 90 days following the event.

Management will also be participating in one-on-one investor meetings throughout the conference. Investors interested in scheduling a meeting with the Rezolute management team should contact their Jefferies representative.

About Rezolute, Inc.

Rezolute strives to disrupt current treatment paradigms by developing transformative therapies for devastating rare and chronic metabolic diseases. Its novel therapies hold the potential to significantly improve outcomes and to reduce the treatment burden for patients, treating physicians and the healthcare system. Rezolute is steadfast in its mission to create a profound, positive and lasting impact on the lives of patients. Patient, clinician and advocate voices are integrated in the Company’s drug development process. Rezolute places an emphasis on understanding the patient’s lived experiences, enabling the Company to boldly address a range of severe conditions. For more information, visit www.rezolutebio.com.

Contacts:

Rezolute, Inc.
Christen Baglaneas
cbaglaneas@rezolutebio.com
508-272-6717

LHA Investor Relations
Tirth T. Patel
tpatel@lhai.com
212-201-6614

FAQ

What is Rezolute's stock symbol?

Rezolute's stock symbol is RZLT.

When is Rezolute participating in the Jefferies Global Healthcare Conference?

Rezolute will participate on June 6, 2024, at 1:00 p.m. ET.

Will there be a live webcast of Rezolute's presentation at the Jefferies Global Healthcare Conference?

Yes, a live webcast will be available on the company's investor relations website and archived for 90 days.

How can investors schedule one-on-one meetings with Rezolute's management at the Jefferies Global Healthcare Conference?

Investors should contact their Jefferies representative to schedule a one-on-one meeting with Rezolute's management.